Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I3 | Q14994 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4790068 | 0.91 | CYP1A2 (0.40) | CHRM3KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL2998707 | 0.86 | KDM4E (0.36) | KDM4EALDH1A1CXCR4 | |
| SCHEMBL923678 | 0.84 | PRKCA (0.36) | OPRM1OPRD1OGFRL1KDM4EALDH1A1 | |
| SCHEMBL2157399 | 0.83 | BRD9 (0.38) | CHRM3KDM4EALDH1A1BRD4HPGD | |
| SCHEMBL2988625 | 0.81 | PTGDR (0.35) | BRD4CCKBRL3MBTL1 | |
| SCHEMBL2157328 | 0.80 | KDM4E (0.31) | KDM4E | |
| SCHEMBL2156279 | 0.79 | CYP2D6 (0.34) | KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL2156912 | 0.79 | NR1H4 (0.31) | KDM4EALDH1A1HPGDL3MBTL1CXCR4 | |
| SCHEMBL2994392 | 0.76 | KDM4E (0.40) | KDM4EALDH1A1HPGD | |
| SCHEMBL3563946 | 0.75 | PRKCA (0.35) | OPRM1OPRD1OGFRL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973026-B2 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-07-05 | — | — | US | disclosed |
| US-20090105227-A1 | Thienopyrroles As Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105227-A1 | Thienopyrroles As Antiviral Agents | ZC3HAV1, HAVCR2, ZC3HAV1L | NR1I3 339/4885OPRM1 716/4885OPRD1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.